Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 6:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Heparin Induced Thrombocytopenia Clear all
Completed Phase 3 Interventional

Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)

NCT00073580
View directory record Official record
Conditions
Thrombocytopenia, Thrombosis, Cardiac Disease, Coronary Artery Bypass Surgery
Interventions
Angiomax (bivalirudin) anticoagulant
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Jun 26, 2026, 6:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects

NCT05325346
View directory record Official record
Conditions
Heparin-induced Thrombocytopenia
Interventions
VLX-1005, Argatroban
Drug
Lead sponsor
Veralox Therapeutics
Industry
Eligibility
19 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Jun 26, 2026, 6:30 AM EDT
Not listed No phase listed Observational

Validating 4Ts for Heparin Induced Thrombocytopenia (HIT)

NCT00946400
View directory record Official record
Conditions
Heparin-Induced Thrombocytopenia
Interventions
Scoring 4Ts and Chong scale, Blood draw
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2009 · Synced Jun 26, 2026, 6:30 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)

NCT03594045
View directory record Official record
Conditions
Heparin-induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis
Interventions
Apixaban
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Jun 26, 2026, 6:30 AM EDT
Not listed Phase 3 Interventional

Multi-Center Single Arm Trial to Determine The Effectiveness of Warfarin Therapy Duration For Heparin-Induced Thrombocytopenia (HIT)

NCT03147638
View directory record Official record
Conditions
Heparin-induced Thrombocytopenia
Interventions
Warfarin, NOAC
Drug
Lead sponsor
Marshall University
Other
Eligibility
18 Years to 97 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Huntington, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Jun 26, 2026, 6:30 AM EDT
Completed No phase listed Observational

Heparin Antibodies in Intensive Care Unit Patients (HAICU)

NCT00283322
View directory record Official record
Conditions
Heparin-Induced Thrombocytopenia
Interventions
blood samples (2)
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Orlando, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Jun 26, 2026, 6:30 AM EDT
Terminated No phase listed Observational Results available

Evaluating the Presence of Blood Clots in People With Heparin-Induced Thrombocytopenia (HIT) (The HOT Study)

NCT00594685
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Not listed
Lead sponsor
Carelon Research
Other
Eligibility
6 Months and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
21
States / cities
Atlanta, Georgia • Iowa City, Iowa • New Orleans, Louisiana + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2013 · Synced Jun 26, 2026, 6:30 AM EDT
Completed Phase 4 Interventional Results available

Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis

NCT00913133
View directory record Official record
Conditions
Thrombosis
Interventions
Desirudin
Drug
Lead sponsor
Canyon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
16
States / cities
Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Jun 26, 2026, 6:30 AM EDT
Suspended Phase 2 Interventional

Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin

NCT02501434
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage, Neurobehavioral Manifestations, Vasospasm, Intracranial, Intracranial Aneurysm, Heparin-induced Thrombocytopenia Type II
Interventions
Continuous Low-Dose IV Unfractionated Heparin Infusion
Drug
Lead sponsor
Robert F. James
Other
Eligibility
18 Years to 70 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
9
States / cities
New Haven, Connecticut • Gainesville, Florida • Tallahassee, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Jun 26, 2026, 6:30 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery

NCT00329433
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Desirudin (Iprivask™), Heparin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Jun 26, 2026, 6:30 AM EDT
Terminated Phase 2 Interventional Results available

Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

NCT00673439
View directory record Official record
Conditions
Heparin-Induced Thrombocytopenia
Interventions
fondaparinux, warfarin
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Jun 26, 2026, 6:30 AM EDT
Completed No phase listed Observational

Heparin Induced Thrombocytopenia: Pharmacoeconomics

NCT00456001
View directory record Official record
Conditions
Heparin Induced Thrombocytopenia (HIT)
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2009 · Synced Jun 26, 2026, 6:30 AM EDT
Withdrawn Phase 4 Interventional

Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients

NCT00759083
View directory record Official record
Conditions
Heparin-Induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis Syndrome
Interventions
bivalirudin
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jun 26, 2026, 6:30 AM EDT
Completed No phase listed Observational

Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2

NCT02526485
View directory record Official record
Conditions
Heparin-induced Thrombocytopenia
Interventions
Blood Draw
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Jun 26, 2026, 6:30 AM EDT
Completed Phase 4 Interventional

Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin

NCT00039858
View directory record Official record
Conditions
Thrombocytopenia, Thrombosis
Interventions
Argatroban
Drug
Lead sponsor
Encysive Pharmaceuticals
Industry
Eligibility
Up to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
13
States / cities
Los Angeles, California • Orange, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2007 · Synced Jun 26, 2026, 6:30 AM EDT
Completed Phase 3 Interventional

Angiomax in Patients With HIT/HITTS Type II Undergoing CPB

NCT00079508
View directory record Official record
Conditions
Cardiovascular Disease, Coronary Artery Bypass Surgery
Interventions
Angiomax (bivalirudin)
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 9, 2011 · Synced Jun 26, 2026, 6:30 AM EDT
Completed No phase listed Observational Results available

Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study

NCT01178333
View directory record Official record
Conditions
Heparin Induced Thrombocytopenia
Interventions
Not listed
Lead sponsor
Carelon Research
Other
Eligibility
Not listed
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
21
States / cities
Iowa City, Iowa • New Orleans, Louisiana • Baltimore, Maryland + 12 more
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Jun 26, 2026, 6:30 AM EDT
Recruiting No phase listed Observational

Pharmacogenomics of Heparin-Induced Thrombocytopenia

NCT02717039
View directory record Official record
Conditions
Heparin-induced Thrombocytopenia
Interventions
Blood Draw
Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Jun 26, 2026, 6:30 AM EDT
Completed No phase listed Observational

Heparin-Induced Thrombocytopenia Registry

NCT00456326
View directory record Official record
Conditions
Heparin-Induced Thrombocytopenia
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2008 · Synced Jun 26, 2026, 6:30 AM EDT
Completed Phase 3 Interventional

Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)

NCT00043940
View directory record Official record
Conditions
Heparin-Induced Thrombocytopenia, Thrombosis
Interventions
bivalirudin
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2011 · Synced Jun 26, 2026, 6:30 AM EDT
Terminated Phase 3 Interventional

Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban

NCT03809481
View directory record Official record
Conditions
Heparin-induced Thrombocytopenia
Interventions
Danaparoid Sodium, Argatroban
Drug
Lead sponsor
Aspen Global Incorporated
Industry
Eligibility
2 Weeks to 100 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Gainesville, Florida • Minneapolis, Minnesota • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Jun 26, 2026, 6:30 AM EDT
Terminated Phase 4 Interventional Results available

A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome

NCT00787332
View directory record Official record
Conditions
Suspected Heparin-Induced Thrombocytopenia
Interventions
Desirudin or Argatroban®
Drug
Lead sponsor
Canyon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
24
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Orlando, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Jun 26, 2026, 6:30 AM EDT
Completed No phase listed Observational

EMR Tool Impact on HIT Documentation and Management

NCT05439265
View directory record Official record
Conditions
Heparin, Thrombocytopenia, Electronic Health Records
Interventions
Electronic medical record order panel and resident involvement
Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Jun 26, 2026, 6:30 AM EDT
Completed Phase 1 Interventional Results available

Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis

NCT00412464
View directory record Official record
Conditions
Thrombosis, Heparin-induced Thrombocytopenia
Interventions
Fondaparinux
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Los Angeles, California • Orange, California • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Jun 26, 2026, 6:30 AM EDT